Records containing: Rituximab

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

All FDA submission records EMA medicine records ClinicalTrials.gov record updates ClinicalTrials.gov records with results posted

CLINICAL_TRIALS study record update · 2026-04-16
Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study
CLINICAL_TRIALS study record update · 2024-07-31
Clinical Follow-up Study of Rituximab in the Treatment of Nephrotic Syndrome in Children
CLINICAL_TRIALS study record update · 2023-08-25
Study of Rituximab Monotherapy VS Steroid Therapy on Children With New-onset Nephrotic Syndrome: A Randomized Controlled Trial
CLINICAL_TRIALS study record update · 2022-05-09
Prospective Multicenters Clinical Cohort Study on Efficacy and Safety of Stratified Treatment for Chinese Children With Burkitt Lymphoma/Diffuse Large B-cell Lymphoma
CLINICAL_TRIALS study record update · 2022-05-02
Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis
Organize your saved records without ads with Plus.
CLINICAL_TRIALS study record update · 2022-04-13
Population Pharmacokinetic-pharmacodynamic Study of Rituximab in Children With Blood Diseases
CLINICAL_TRIALS study record update · 2021-06-02
Registry Study for COVID19 Vaccination Efficacy in Patients With a Treatment History of Rituximab.
CLINICAL_TRIALS study record update · 2020-06-16
Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma: An Exploratory Small Sample, Phase II, Single-center Clinical Trail
CLINICAL_TRIALS study record update · 2017-12-14
A Non-randomized, Open-label, Phase II Study of Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not Suitable for Transplantation